Alto Neuroscience (ANRO) EBIT (2023 - 2026)
Alto Neuroscience (ANRO) posted EBIT of -$27.1 million for Q1 2026, down 59.12% sequentially from -$17.1 million in Q4 2025, and down 73.12% YoY from -$101.0 million in Q1 2025.
Alto Neuroscience (ANRO) EBIT (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported EBIT for 4 years, with the latest figure at -$27.1 million in Q1 2026.
- Quarterly EBIT fell 73.12% year-over-year to -$27.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.8 million (down 11.34% YoY) and the FY2025 annual result came in at -$66.4 million, up 3.27% from the prior year.
- EBIT eased to -$27.1 million in Q1 2026 per ANRO's latest filing, from -$17.1 million in the prior quarter.
- Over five years, EBIT peaked at -$7.2 million in Q1 2023 and troughed at -$27.1 million in Q1 2026.
- A 4-year average of -$15.4 million and a median of -$15.7 million in 2025 frame the typical range for EBIT.
- The sharpest annual moves came in 2024 and 2025: EBIT sank 101.0% in 2024, then climbed 20.84% in 2025.
- Over 4 years, EBIT stood at -$11.8 million in 2023, then slumped by 44.47% to -$17.0 million in 2024, then fell by 0.34% to -$17.1 million in 2025, then slumped by 59.12% to -$27.1 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$27.1 million, -$17.1 million, and -$15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | -29.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.13 Mn |
| Mar 31, 2026 | -27.14 Mn |
| Dec 31, 2025 | -17.06 Mn |
| Sep 30, 2025 | -14.95 Mn |
| Jun 30, 2025 | -18.68 Mn |
| Mar 31, 2025 | -15.68 Mn |
| Dec 31, 2024 | -17.00 Mn |
| Sep 30, 2024 | -18.89 Mn |
| Jun 30, 2024 | -18.34 Mn |
| Mar 31, 2024 | -14.39 Mn |
| Dec 31, 2023 | -11.77 Mn |
| Sep 30, 2023 | -9.72 Mn |
| Jun 30, 2023 | -9.13 Mn |
| Mar 31, 2023 | -7.20 Mn |